National Advertising Division Finds Certain DUPIXENT Claims Supported; Recommends Sanofi Modify or Discontinue Other Claims
· bbb national programs
AI Briefing
- • NAD finds certain DUPIXENT claims supported, but recommends modification or discontinuation of others.
- • Sanofi challenged by Galderma Laboratories over long-lasting clearer skin, fast itch relief claims.
- • NAD recommends Sanofi modify or discontinue prescriber-facing day-2 itch relief claims.
Context
The National Advertising Division found certain claims made by Sanofi S.A. to be supported. Sanofi faced a challenge from Galderma Laboratories, L.P. regarding its advertising claims. The division reviewed claims about long-lasting clearer skin, fast itch relief, and a prescriber-facing day-2 itch relief claim.
The National Advertising Division recommended that Sanofi modify or discontinue some of its claims. This decision affects how Sanofi can advertise its product, specifically regarding claims of long-lasting clearer skin and fast itch relief.
Advertisement